Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Amanat Acquisition Corp.AMAN · Entity 6741 | Director | May 18, 2026 | May 19, 2026 |
| Avalo Therapeutics, Inc.CERC · Entity 4936 | VP, Business Development | December 20, 2018 | April 02, 2019 |
| Jasper Therapeutics, Inc.JSPR · Entity 7588 | Director | July 31, 2026 | August 04, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Amanat Acquisition Corp.
Report date May 18, 2026 · Filed May 19, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | IndirectSee footnote | Not disclosed |
Reported balance
Holding disclosure · report date 2026-05-18 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The reporting person beneficially owns 25,000 Class B ordinary shares which will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-295170) ("Registration Statement") and have no expiration date. F2: For his services as a director, the Reporting Person receives indirect interest in founder shares through membership interests in the Company's sponsor, Amanat Sponsor Holdings LLC. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person beneficially owns 25,000 Class B ordinary shares which will automatically convert into Class A ordinary shares concurrently with or immediately following the consummation of the Issuer's initial business combination or earlier at the option of the holder on a one-for-one basis, subject to adjustment for share sub-divisions, share capitalizations, reorganizations, recapitalizations and the like, and certain anti-dilution rights as described under the heading "Description of Securities--Founder Shares and Private Placement Shares" in the Issuer's registration statement on Form S-1 (File No. 333-295170) ("Registration Statement") and have no expiration date.
F2: For his services as a director, the Reporting Person receives indirect interest in founder shares through membership interests in the Company's sponsor, Amanat Sponsor Holdings LLC.
Avalo Therapeutics, Inc.
Report date December 20, 2018 · Filed April 02, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,634,771 |
Reported balance
After 2018-12-20 transaction · row 1
1 source rowRow 1 · 2018-12-20 · Disposition to issuer · Disposed 6,871 · Balance 1,634,771 F1: Received in exchange for 1,000,000 shares of Ichorion Therapeutics, Inc. common stock in connection with the merger of Ichorion Therapeutics, Inc. into the Issuer. On September 25, 2018 the closing price of the Issuer's common stock was $4.55 per share. This transaction reports a disposition of shares to accurately reflect a working capital adjustment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.22 · Expires 2029-04-01 | Direct | 145,000 |
Reported balance
After 2019-04-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-04-01 · Grant · Acquired 145,000 · Balance 145,000 F2: One fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months. |
Filing footnotes · ownership attribution and instrument terms
F1: Received in exchange for 1,000,000 shares of Ichorion Therapeutics, Inc. common stock in connection with the merger of Ichorion Therapeutics, Inc. into the Issuer. On September 25, 2018 the closing price of the Issuer's common stock was $4.55 per share. This transaction reports a disposition of shares to accurately reflect a working capital adjustment.
F2: One fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months.
Jasper Therapeutics, Inc.
Report date July 31, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to BuySEC Table II · derivative / convertible security · Conversion / exercise price $0.63 · Expires 2036-07-31 | Direct | 7,500 |
Reported balance
After 2026-07-31 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-07-31 · Grant · Acquired 7,500 · Balance 7,500 F1: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 31, 2026 Filed Aug 4, 2026 20:10 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (Right to Buy · Derivative | 7,500 | $0.00 Strike: $0.63 | $0.00 |
DisclosureSEC source: 0001213900-26-085190 · ownership.xml · derivative · entry 1 Crutcher Patrick J · CIK 0001754540 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,500 Underlying: Voting Common Stock · 7,500 shares Expires 2036-07-31 F1 · derivative.exercise_date: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date. F1 · derivative.expiration_date: Granted automatically pursuant to the Issuer's Non-Employee Director Compensation Policy, which provides that non-employee directors are automatically granted an option to purchase 7,500 shares on the date of each of the Issuer's annual meeting of stockholders, which shall vest in full upon the first anniversary of the date of the grant, subject to the director's continued service through such vesting date. Read SEC document |
| July 20, 2026 Filed Jul 21, 2026 00:38 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | PurchaseNon-Voting Convertible Preferred Stock · Derivative | 888 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001213900-26-079764 · ownership.xml · derivative · entry 2 Crutcher Patrick J · CIK 0001754540 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 888 Underlying: Voting Common Stock · 888 shares Expires not disclosed F2 · derivative.exercise_price: On July 16, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026. F3 · derivative.exercise_price: On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock ("Voting Common Stock"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date. F2 · shares: On July 16, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026. F3 · shares: On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock ("Voting Common Stock"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date. F2 · price: On July 16, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026. F3 · price: On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock ("Voting Common Stock"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date. F2 · derivative.exercise_date: On July 16, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026. F3 · derivative.exercise_date: On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock ("Voting Common Stock"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date. F2 · derivative.expiration_date: On July 16, 2026, the Issuer entered into a securities purchase agreement (the "Purchase Agreement") with certain accredited investors, including the Reporting Person. Pursuant to the terms of the Purchase Agreement, the Issuer issued and sold the referenced shares of preferred stock to the Reporting Person in a private placement, which closed on July 20, 2026. F3 · derivative.expiration_date: On the third business day following the receipt of stockholder approval of the conversion of the preferred stock, each share of preferred stock shall automatically convert into 61 shares of the Issuer's voting common stock ("Voting Common Stock"), subject to certain limitations, including that a holder of preferred stock is prohibited from converting shares of preferred stock into shares of Voting Common Stock if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than a specified percentage (to be established by the holder between 4.9% and 19.9%) of the total number of shares of Voting Common Stock issued and outstanding immediately after giving effect to such conversion. The preferred stock has no expiration date. Read SEC document |
| July 16, 2026 Filed Jul 21, 2026 00:38 UTC | Jasper Therapeutics, Inc. JSPR · Entity 7588 | GrantStock Option (Right to Buy · Derivative | 15,000 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001213900-26-079764 · ownership.xml · derivative · entry 1 Crutcher Patrick J · CIK 0001754540 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Voting Common Stock · 15,000 shares Expires not disclosed F1 · derivative.exercise_date: The shares shall vest as follows: 25% on the one-year anniversary of the date of grant and the remaining shares shall vest in equal monthly installments over the next 36 months until fully vested, subject to continuous service through each applicable vesting date. F1 · derivative.expiration_date: The shares shall vest as follows: 25% on the one-year anniversary of the date of grant and the remaining shares shall vest in equal monthly installments over the next 36 months until fully vested, subject to continuous service through each applicable vesting date. Read SEC document |
| April 01, 2019 Filed Apr 2, 2019 23:28 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantStock Option (Right to Buy) · Derivative | 145,000 | $0.00 Strike: $6.22 | $0.00 |
DisclosureSEC source: 0001578563-19-000012 · primary_doc.xml · derivative · entry 2 Crutcher Patrick J · CIK 0001754540 · VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,000 Underlying: Common Stock · 145,000 shares Expires 2029-04-01 F2 · derivative.exercise_date: One fourth of the shares subject to the stock option will vest on the first anniversary of the date of grant, and the remaining three-fourths of the shares subject to the stock option will vest in equal monthly installments over the following 36 months. Read SEC document |
| December 20, 2018 Filed Apr 2, 2019 23:28 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | Disposition to issuerCommon Stock | 6,871 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001578563-19-000012 · primary_doc.xml · nonDerivative · entry 1 Crutcher Patrick J · CIK 0001754540 · VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,634,771 F1 · price: Received in exchange for 1,000,000 shares of Ichorion Therapeutics, Inc. common stock in connection with the merger of Ichorion Therapeutics, Inc. into the Issuer. On September 25, 2018 the closing price of the Issuer's common stock was $4.55 per share. This transaction reports a disposition of shares to accurately reflect a working capital adjustment. Read SEC document |
| September 25, 2018 Filed Sep 27, 2018 20:29 UTC | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantCommon Stock | 1,645,286 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001578563-18-000015 · primary_doc.xml · nonDerivative · entry 1 Crutcher Patrick J · CIK 0001754540 · VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,645,286 F1 · price: Received in exchange for 1,000,000 shares of Ichorion Therapeutics, Inc. common stock in connection with the merger of Ichorion Therapeutics, Inc. into the Issuer. On September 25, 2018 the closing price of the Issuer's common stock was $4.55 per share. Read SEC document |
| September 25, 2018 Filed Oct 4, 2018 20:56 UTC Amendment | Avalo Therapeutics, Inc. CERC · Entity 4936 | GrantCommon Stock | 1,641,642 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001754540-18-000001 · primary_doc.xml · nonDerivative · entry 1 Crutcher Patrick J · CIK 0001754540 · VP, Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,641,642 F1 · price: Received in exchange for 1,000,000 shares of Ichorion Therapeutics, Inc. common stock in connection with the merger of Ichorion Therapeutics, Inc. into the Issuer. On September 25, 2018 the closing price of the Issuer's common stock was $4.55 per share. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.